TARGETED DRUG DELIVERY TO CANCER CELLS: ADVANCES IN NANOTECHNOLOGY
Advancement in science and technology has brought a remarkable change in therapy of cancer. Particles are engineered in such a way so that they are attracted to diseased cells, which allows direct treatment of cancer cells. Drug delivery systems control the location in the body where it is released and the rate at which a drug is released. Conventional chemotherapeutic possess some serious side effects, including damage of the immune system and other various types of organs with rapidly proliferating cells due to nonspecific targeting, lack of solubility, and inability to enter the core part of the tumor which results in impaired treatment with the reduced dose and low survival rate. Nanoparticles can be programmed in such a way so that it can recognize the cancerous cells by giving selective and accurate drug delivery avoiding interaction with the healthy cells. The main aim of this review focuses on various strategies for cancer cell targeting. It also discusses specific drug delivery by nanoparticles inside the cells, illustrating many successful research in the field of cancer therapy.
Williams et al. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. J Control Release 2003;91(1-2):167â€“72.
Leroux JC, Allemann E, De Jaeghere F, Duelker E, Gurny R. Biodegradable nanoparticlesâ€”From sustained release formulation to improved site specific drug delivery. J Control Release 1996;30:339â€“50.
Shanmugam K, Subramanian P. Extracellular and intracellular synthesis of silver nanoparticles. Asian J Pharm Clin Res 2016;9(14):133-139.
Yeole MP, Dhole SN, Kulkarni NS. Peptide nanomedicine in cancer treatment. Asian J Pharm Clin Res 2013;6(2):28-32.
Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009;30(11):592â€“599.
Sutradhar KB, Amin ML. Nanoemulsions: increasing possibilities in drug delivery. European Journal of Nanomedicine 2013;5(2):97â€“110.
Praetorius NP, Mandal TK. Engineered nanoparticles in cancer therapy. Recent Pat Drug Deliv Formul 2007;1(1):37â€“51.
Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006;6(9):688â€“701.
Nagahara et al. Strategic workshops on cancer nanotechnology. Cancer Research 2010;70(11):4265â€“68.
Nguyen KT. Targeted nanoparticles for cancer therapy: promises and challenges. J Nanosci Nanotechnol 2011;2:103.
Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002;54(5):631â€“51.
Jeon SI, Lee JH, Andrade JD, de Gennes PG. Protein-surface interactions in the presence of polyethylene oxide: I. Simplified theory. J Colloid Interface Sci 1991;142(1):149â€“158.
Tallury P, Kar S, Bamrungsap S, Huang YF, Tan WH, Santra. Ultra-small water-dispersible fluorescent chitosan nanoparticles: synthesis, characterization and specific targeting. Chemical Communications 2009;17:2347â€“2349.
Francis MF, Cristea M, Winnik FM. Polymeric micelles for oral drug delivery: why and how. Pure and Applied Chemistry 2004;76:1321â€“1335.
Kirpotin DB, Drummond DC et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66(13):6732â€“6740.
Herbst RS. Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology, Biology, Physics 2004;59(2):21â€“6.
Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009;13(3):256â€“62.
Mansoori GA, Mohazzabi P, McCormack P, Jabbari S. Nanotechnology in cancer prevention, detection and treatment: bright future lies ahead. World Review of Science, Technology and Sustainable Development 2007;4:226â€“57.
Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000;41(2):147â€“62.
Kukowska-Latallo et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005;65(12):5317â€“5324.
Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14(5):1310â€“1316.
Pastorino et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature specific ligands potentiates therapeutic efficacy. Cancer Res 2006;66(20):10073â€“10082.
Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin. Immunol 2006;121(2):159â€“176.
Kawamoto M, Horibe T, Kohno M, Kawakami K. A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells. BMC Cancer 2011;11:359.
Daniels TR, Bernabeu E, RodrÃguez JA et al. Transferrin receptors and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 2012;1820(3):291â€“317, 2012.
Minko T. Drug targeting to the colon with lectins and neoglycoconjugates. Adv Drug Deliv Rev 2004;56(4):491â€“509.
Ying et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release 2010;141(2):183â€“192.
Wang YC, Liu XQ, Sun TM, Xiong MH, Wang J. Wang. Functionalized micelles from block copolymer of polyphosphoester and poly(epsilon-caprolactone) for receptor-mediated drug delivery. J Control Release 2008;128(1):32â€“40.
Eliaz RE, Nir S, Marty C, Szoka FC Jr. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res 2004;64(2):711â€“8.
Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res 2003;9(17):6551â€“9.
Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release 2004;96(2):273â€“283.
Mamot et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005;65:11631â€“11638.
Cheng et al. Functionalized thermoresponsive micelles self-assembled from biotinPEG-b-P(NIPAAm-co-HMAAm)-b-PMMA for tumor cell target. Bioconjug Chem 2008;19:1194â€“1201.
Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 2004;12:461â€“471.
Berthod F. Fibroblasts and endothelial cells: the basic angiogenic unit. In Santulli G, editor. Angiogenesis insights from a systematic overview. New York: Nova Science; 2013. p. 145-58.
Birbrair et al. Pericytes at the intersection between tissue regeneration and pathology. Clin Sci 2015;128(2):81â€“93.
Birbrair et al. Type-2 pericytes participate in normal and tumoral angiogenesis. Am J Physiol Cell Physiol 2014;307(1):25â€“38.
Chaplain MAJ. Mathematical modelling of angiogenesis. J NeuroOncol 2000;50:37â€“51.
Folkman J. Incipient angiogenesis. J Natl Cancer Inst 2000;92:94-95.
Weidner et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84(24):1875â€“87.
Fukumura D, Jain RK. Imaging angiogenesis and the microenvironment. APMIS 2008;116:695â€“715.
Dhanabal M, Jeffers M, Larochelle WJ. Anti-angiogenic therapy as a cancer treatment paradigm. Curr Med Chem 2005;5:115â€“130.
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2(12):751â€“760.
Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69(3):11â€“16.
Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008;26(1):57â€“64.
Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006;11(17â€“18):812â€“818.
Bae YH. Drug targeting and tumor heterogeneity. J Control Release 2009;133(1):2â€“3.
Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 2004;4(10):806â€“813.
Liu Y, Li K, Pan J, Liu B, Feng SS. Feng. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials 2010;31(2):330â€“338.
Brewer E, Coleman J, Lowman A. Emerging technologies of polymeric nanoparticles in cancer drug delivery. J Nanomater 2011;2011:1â€“10.
Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 2009;136:21â€“29.
Cirstoiu-Hapca A, Buchegger F, Bossy L, Kosinski M, Gurny R, Delie F. Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells. Eur J Pharm Sci 2009;38:230â€“237.
Kos J, Obermajer N, Doljak B, Kocbek P, Kristl J. Inactivation of harmful tumour-associated proteolysis by nanoparticulate system. â€ŽInt J Pharm 2009;381:106â€“112.